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Abstract: Leber congenital amaurosis (LCA) is a rare inherited retinal disorder affecting
approximately 1:50,000 people worldwide. So far, mutations in 25 genes have been associated
with LCA, with CEP290 (encoding the Centrosomal protein of 290 kDa) being the most frequently
mutated gene. The most recurrent LCA-causing CEP290 mutation, c.2991+1655A>G, causes
the insertion of a pseudoexon into a variable proportion of CEP290 transcripts. We previously
demonstrated that antisense oligonucleotides (AONs) have a high therapeutic potential for patients
homozygously harbouring this mutation, although to date, it is unclear whether rescuing one single
allele is enough to restore CEP290 function. Here, we assessed the AON efficacy at RNA, protein
and cellular levels in samples that are compound heterozygous for this mutation, together with a
protein-truncating mutation in CEP290. We demonstrate that AONs can efficiently restore splicing and
increase protein levels. However, due to a high variability in ciliation among the patient-derived cell
lines, the efficacy of the AONs was more difficult to assess at the cellular level. This observation points
towards the importance of the severity of the second allele and possibly other genetic variants present
in each individual. Overall, AONs seem to be a promising tool to treat CEP290-associated LCA, not
only in homozygous but also in compound heterozygous carriers of the c.2991+1655A>G variant.
Keywords: CEP290; antisense oligonucleotides; splicing correction; compound heterozygosity;
Leber congenital amaurosis
1. Introduction
Leber congenital amaurosis (LCA, OMIM 204000) is the most severe subtype of inherited retinal
disease (IRD), and is characterized by a congenital visual impairment, progressive degeneration of
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photoreceptor cells, sensory nystagmus, and the absence or significant reduction of electroretinographic
responses in the first year of life [1]. So far, mutations in 25 different genes have been associated with
LCA [2], affecting 1:50,000 individuals [3,4]. Mutations in a gene called the Centrosomal protein of
290 kDa (CEP290) are the most frequent cause of LCA in some populations. The protein encoded by
this gene is localized at the base of the connecting cilium of the photoreceptors, which is an essential
structure to transport proteins from the inner segment, where they are synthesized, to the outer
segment, where phototransduction takes place. [5,6]. CEP290 is expressed in almost all cell types
of the body, and, in addition to its role in cilium assembly and transport [5,7], is involved in cell
division [8]. As a consequence, mutations in this gene can cause a broad spectrum of disorders ranging
from purely retinal disease (LCA), to systemic forms such as Senior–Løken, Joubert or Meckel–Gruber
syndrome [9,10] which have also renal phenotypes associated.
Despite the existing high genetic heterogeneity in LCA, one particular mutation in CEP290,
c.2991+1655A>G, accounts for 15% of all LCA cases in some European and North-American
populations [9,11–13]. The c.2991+1655A>G mutation creates a strong splice donor site that is
recognized by the splicing machinery, introducing a 128-bp pseudoexon with a premature stop
codon into a proportion of mRNA transcripts [13]. Initially, the ratio of aberrant and correct transcripts
observed in fibroblast and lymphoblast cells was 1:1, and therefore the cause of the disease was thought
to be a haploinsufficiency [13–15]. However, very recently, the use of induced pluripotent stem cell
(iPSC)-technology showed that up to 90% of the CEP290 mRNA transcripts contained the pseudoexon
upon differentiation of patient-derived iPSCs to photoreceptor-like cells [16], most probably due to
specific retinal splicing factors that are not present in other cell types.
The recurrence of this intronic mutation makes it an interesting target for genetic therapy.
Over the last years, we and others have shown that antisense oligonucleotides (AONs) are a powerful
therapeutic tool to treat IRDs [14–20]. These small oligonucleotides can bind complementary to
the pre-mRNA, and can modulate pre-mRNA splicing by including or excluding (pseudo)exons, or
degrading aberrant transcripts [21]. For the deep-intronic c.2991+1655A>G variant in CEP290, AONs
have been demonstrated to restore splicing, protein levels and ciliation in patient-derived immortalized
lymphoblastoid cells [14], fibroblasts [15,17] and photoreceptor-like cells [16]. In addition, these
molecules were able to restore CEP290 splicing in the retina of a transgenic humanized mouse model,
without creating any damage in the retina [17]. All these studies were performed in homozygous
patient-derived cells or animal models. In this work, we aimed to assess the efficacy of AONs
to correct CEP290 splicing and the cellular phenotype in compound heterozygous cases, by using
patient-derived fibroblast cells where only one CEP290 allele is represented by the deep-intronic
c.2991+1655A>G mutation.
2. Results
2.1. Clinical Information of the LCA-Affected Individuals
Six patients were previously diagnosed with LCA caused by biallelic CEP290 mutations. In all
six cases, at least one of the two alleles harboured the deep-intronic mutation c.2991+1655A>G.
Three patients were homozygous for this variant (LCA1-LCA3), whereas three others (LCA4-LCA6)
carried protein-truncating mutations on the other allele. In two patients the p.Gly1890* variant
was reported as the second disease-causing allele (LCA4 and LCA6), while in the other (LCA5),
the p.Lys1575* mutation was present. In addition, we also obtained a skin biopsy from one of
the parents of the homozygous LCA-affected individual LCA3, thus heterozygously carrying the
c.2991+1655A>G allele (HET1). All affected individuals were diagnosed with LCA soon after birth
and were otherwise healthy. In adulthood, subject LCA6 was found to be infertile due to immotile
spermatozoa. This might fit within the spectrum of CEP290-associated non-ocular features, although
there is no strong evidence supporting that. A summary of the genetic and clinical information for
each individual is shown in Table 1.
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Table 1. Genetic and clinical information of the individuals.
Individual Cell Line Gender Allele 1(cDNA)
Allele 1
(Protein)
Allele 2
(cDNA)
Allele 2
(Protein)
Ocular
Phenotype Age at Onset
Extra-Ocular
Features
Control 1 CON1 Female + + + + Healthy
Control 2 CON2 Female + + + + Healthy
Control 3 CON3 Male + + + + Healthy
LCA 1 LCA1 Male c.2991+1655A>G p.Cys998* c.2991+1655A>G p.Cys998* LCA birth none
LCA 2 LCA2 Female c.2991+1655A>G p.Cys998* c.2991+1655A>G p.Cys998* LCA birth none
LCA 3 LCA3 Female c.2991+1655A>G p.Cys998* c.2991+1655A>G p.Cys998* LCA birth none
LCA 4 LCA4 Female c.2991+1655A>G p.Cys998* c.5668G>T p.Gly1890* LCA/EORP earlychildhood none
LCA 5 LCA5 Male c.2991+1655A>G p.Cys998* c.4723A>T p.Lys1575* LCA birth none
LCA 6 LCA6 Male c.2991+1655A>G p.Cys998* c.5668G>T p.Gly1890* LCA birth (basedon anamnesis)
immotile
spermatozoa
Unaffected
mother LCA3 HET1 Female c.2991+1655A>G p.Cys998* + + Healthy
CON: control; LCA: Leber congenital amaurosis; HOM: homozygous; COMPHET: compound heterozygous; UNAFF: unaffected; HET: heterozygous; EORP: early-onset retinitis
pigmentosa; (+) wild-type.
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2.2. AON Efficacy at RNA Level
Fibroblast cell lines were generated from skin biopsies of all six LCA patients (LCA1-LCA6)
and the heterozygous carrier of the c.2991+1655A>G mutation (HET1). In addition, age and
gender-matched control cell lines were used. Subsequently, we studied the effect of AON delivery at
the RNA, protein and cellular level. Previously, we have identified an AON molecule that is able to
efficiently restore CEP290 pre-mRNA in cell lines derived from patients harbouring the deep-intronic
mutation in a homozygous manner [14,17]. In this experiment, we delivered the same AON to all the
cell lines at a final concentration of 0.1 µM, and 48 h post-transfection, cells were subjected to RT-PCR
analysis. In all seven fibroblast cell lines carrying the deep-intronic variant (LCA1 to LCA6 and HET1),
the pseudoexon was detected and efficiently skipped upon AON delivery (Figure 1). In addition,
as expected, in the compound heterozygous cell lines (LCA4, LCA5 and LCA6), as well as the one
corresponding to the carrier (HET1), a less intense pseudoexon-containing band was detected, due
to the fact that the mutation is only present on one of the two alleles. No pseudoexon was detected
in any of the control lines (CON1 to CON3) and the delivery of the AON did not appear to alter the
normal splicing of CEP290.
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Figure 1. AON rescue at RNA level in all cell lines. RT-PCR analysis of CEP290 transcripts. The upper
band corresponds to the transcript containing the 128-bp pseudoexon. The lower band is the correctly
spliced transcript. In all cases that showed pseudoexon inclusion, the splicing was corrected upon
AON delivery (+). In the lower panel, actin (ACTB) expression is shown as a loading control. Cell lines
are indicated with CON (control), LCA (patient) and HET (carrier). MQ corresponds to the negative
control of the PCR. (−) means untransfected cells.
2.3. AON Efficacy at Protein Level
We next assessed whether the splicing correction at the RNA level could be translated to an
increase in the CEP290 protein levels. For that, an immunodetection of the protein by Western blot
was performed. Given the amount of samples, it was not possible to have a direct comparison of
all samples on the same gel, and thus we compared untreated versus AON-treated conditions for
each cell line. A representative image of the CEP290 protein levels in all cell lines is illustrated in
Figure 2A, whereas the quantification of the bands of all replicates is presented in Figure 2B. First,
untreated CON and HET1 cell lines showed higher amounts of CEP290 protein compared to the
LCA cell lines and no statistically significant differences. Only in one of the replicates for CON1 we
observed less CEP290 protein after Tubulin normalization most likely due to some technical limitations.
Furthermore, in the homozygous cell lines (LCA1 and LCA2), a clear increase of the protein levels
was observed. Of note, after the RT-PCR analysis, the LCA3 cell line was not used for protein analysis
and subsequent ciliation studies due to problems in the culturing of this primary cell line. For the
compound heterozygous cell lines (LCA4 to LCA6), also an increase of CEP290 protein was observed,
however it was less evident compared to the homozygous cell lines, but for LCA5 and LCA6 it was a
statistically significant increase. Overall, AON delivery increased the protein levels in all the cell lines
carrying the c.2991+1655A>G variant. Moreover, no differences were detected upon AON delivery in
control fibroblast cells.
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Figure 2. CEP290 protein levels upon AON delivery. (A) Immunodetection of CEP290 protein (upper
panel) and Tubulin (lower panel) in all controls (CON), LCA-affected patients (LCA) and carrier (HET),
in the presence (+) or absence (−) of AON. Tubulin was used as loading control; (B) Quantification
of the CEP290 protein levels using Fiji software. Bands were quantified twice for each replicate and
normalized to Tubulin. Results show the average value for the intensity of the bands and the error
bars indicate the standard deviation. The asterisk (*) indicates statistically significant differences
(p-value < 0.05 using Mann-Whitney test).
2.4. AON Efficacy at Ciliation Level
One characteristic of fibroblast cells carrying mutations in CEP290 is that a cellular phenotype
is present. CEP290 is known to function in cilium transport and within the cell cycle, and previously,
we and others have observed that in fibroblasts derived from individuals with CEP290 mutations,
these cells show shorter cilia, less ciliation and sometimes even a slower growth speed [15–17,22].
AON delivery previously corrected this cellular phenotype in cell lines from patients homozygous
for the c.2991+1655A>G mutation [15–17]. In this study, we used Acetylated Tubulin as a marker of
the axoneme of the cilia (representative images in Figure 3A, images of each condition can be found
in Figure S1). Overall, our ciliation studies showed a high variability in the cilium length, even when
comparing cells from different control individuals. The cilium length of the control cells was not
modified upon AON delivery (Figure 3B). Due to this variability, the AON efficacy was evaluated
solely based on the differences between untreated and AON-treated samples for each individual
cell line. In LCA1 and LCA2 (homozygous) cell lines, a slight increase was detected, even though, in
contrast to our previous study [17], it now was not statistically significant. In contrast, the compound
heterozygous cell lines LCA4, LCA5 and LCA6 did show a statistically significant increase in ciliation.
In the case of the carrier (HET1) cell line, surprisingly, a significant decrease in ciliation was observed
upon AON delivery (Figure 3B).
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Figure 3. Cilium length assessment in fibroblast cells treated with AONs. (A) Representative images
of a control (CON), a homozygous LCA (LCA-HOM), a compound heterozygous LCA (LCA-CHET)
and carrier (HET) cell line. Nuclei are stained with DAPI (blue) and the axoneme of the cilia using
Acetylated Tubulin as a marker (red) in non-treated (NT) and AON-treated (AON) cells. Scale bar
represents 20 µm; (B) Cilium length analysis of all fibroblast cell lines employed for ciliation studies in
the non-treated (−) and AON-treated (+) situation. Control (CON1, CON2 and CON3), ho ozygous
LC (LC 1 and LC 2), co pound heterozygous (LC 4, LC 5 and LC 6) and heterozygous carrier
( ET1) cell lines ere used in this study. Each dot depicts the length of one ciliu and the red line
the average length per group. Statistical analysis as perfor ed using Student’s t-test. p- alues are
indicated in the figure. * p-value < 0.05 a *** p-val e 0.001.
3. Discussion
We here aimed to study whether correcting a single c.2991+1655A>G allele with an AON-based
therapeutic approach, would be sufficient to restore the RNA and protein levels, as well as the cilium
length, in patient fibroblasts obtained from skin biopsies. Previously we identified an AON molecule
that corrected CEP290 pre-mRNA splicing, increased the CEP290 protein levels and restored a cellular
defect in fibroblast cells homozygously carrying the c.2991+1655A>G mutation. These results have
recently led to the initiation of a clinical trial (NCT03140969 [23]), assessing the efficacy of AONs in
patients harbouring this mutation. However, since the majority of LCA patients with CEP290 mutations
are compound heterozygous for the c.2991+1655A>G variant, it is important to also demonstrate the
efficacy of AON-based splice redirection in cells from this group of individuals.
Our study design consisted of three groups of cell lines; the control group, the homozygous group
and the compound heterozygous group, together with one carrier cell line. For RNA analysis, we were
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able to use all cell lines. However, after a very few passages, the CEP290-homozygous cell line LCA3
stopped growing and therefore Western blot and ciliation experiments were impossible to perform.
One of the reasons could be that when the skin biopsy was received, a contamination was suspected,
and the cells were subjected to antifungal treatment with primocin. Any traces of contamination
could not be detected afterwards, but this could have had an effect on their normal growth and/or
morphology. Another possibility is that these cells carry other variants that may influence the normal
cell cycle. In general, we observed that our cell lines were growing at different speeds. On average, the
control cell lines, as well as the one derived from the carrier, had a normal speed. The homozygous
cell lines, with the exception of the LCA3 case, grew moderately slower than controls. Two of the three
cell lines derived from the compound heterozygous patients however grew noticeably slower than
the rest of the cell lines. These differences could be related to the severity of the second CEP290 allele,
which represents a protein-truncating mutation. Importantly, we and others have previously described
that in c.2991+1655A>G homozygous fibroblast cells, the ratio between correct and aberrantly spliced
CEP290 transcripts on average is ~1:1. This indicates that in a homozygous situation, around 50% of the
transcripts are still correct, while in a compound heterozygous situation this is only 25%. Given that
CEP290 has been related to cell division, this could explain the evident differences in growth that are
observed [8,24–26].
The delivery of AONs to cells homozygously harbouring the c.2991+1655A>G mutation was
shown to be effective in restoring CEP290 pre-mRNA splicing, increasing the protein levels and
correcting a ciliary defect [14–17]. However, it was unknown whether correcting one c.2991+1655A>G
allele was sufficient. Taken into account that mutations in CEP290 cause recessive forms of several
diseases, we hypothesized that correcting one allele should be enough to restore CEP290 levels
and function in the cell. Therefore, we assessed fibroblast cells derived from patients carrying
the deep-intronic variant together with a protein-truncating mutation on the second allele. In two
cases, the p.Gly1890* variant (LCA4 and LCA6), and in a third one (LCA5), the p.Lys1575* variant
were present. Previously, both these mutations were reported to be associated with more severe
forms of CEP290-associated diseases, i.e., the p.Gly1890* variant with cerebello-ocular-renal syndrome
(CORS) and Joubert Syndrome, whilst the p.Lys1575* variant with CORS, Senior-Løken syndrome
and Meckel-Grüber syndrome-like (reviewed in [9]). In all cells with the deep-intronic variant, the
128-bp pseudoexon was detected, and it was possible to restore CEP290 splicing upon AON delivery,
independent of the type of mutation present on the second allele. The increase in CEP290 protein
was statistically significant in homozygous lines (LCA1 and LCA2), and compound heterozygous
lines (LCA5 and LCA6). For LCA4 there was an apparent increase. This rise in CEP290 protein levels
also resulted in an increased length of the cilium in all patient-derived cell lines, albeit not always
statistically significant. In our previous study, cell lines LCA1 and LCA2 did show a statistically
significant increase in ciliation and cilium length following AON treatment [17]. The fact that these
cells now only showed a slight increase in ciliation was somehow unexpected. Two explanations for
these findings could be (i) the variability of the cilium length that we now observed in our age- and
gender matched controls; and (ii) the fact that fibroblasts are primary cells, and therefore they could
behave differently after several passages, as we also observed with some control lines in the past.
Before, we have used fibroblast cells between passages p4 and p6, whereas now, we used cells between
passages p9 and p13. Although we always try to match the passage numbers of our compound
heterozygous and control cell lines, this may explain some of the differences we observed between this
and our previous study. Nevertheless, our results indicate that it is possible to increase the CEP290
protein expression and the cilium length upon AON delivery when only one of the two alleles is
represented by the deep-intronic c.2991+1655A>G variant.
In our study, we also used a cell line of an unaffected heterozygous carrier of the c.2991+1655A>G
mutation to assess whether any ciliation defect could be observed in these cells. As expected, the
amount of pseudoexon was low, and levels of protein did not show an evident increase after treatment,
nor a significant decrease compared to the control cells. Surprisingly, although these cells showed
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normal levels of ciliation, a statistically significant decrease of the cilium length was detected upon
AON administration. Even though both groups followed a Gaussian distribution with a relatively
similar cilium length average ± SD of 4.08 µm ± 1.05 for the untreated and 3.88 µm ± 1.09 for the
AON-treated group, the medians differed between groups (4.16 and 3.83 µm, respectively). One would
assume that one reason could be the amount of cilia counted (n = 256 for untreated and n = 209 for the
AON-treated), however this was taken into account when applying the statistical test. When evaluating
the two replicates independently, one showed a statistically significant difference whereas the other
did not. When both replicates were combined, these differences became more evident. All samples
were treated simultaneously so potential technical problems or alterations due to the reagents could be
discarded as this should have then also been observed in other samples. We included age- and gender
matched control cell lines, used as lowest cell passages as possible, and tried to compensate the growth
speed by seeding more or less cells of each cell line. Nevertheless, the variability between samples and
groups was higher than expected.
Parfitt and colleagues recently demonstrated that, by employing induced pluripotent stem cell
technology to generate patient-derived optic cups, the amount of aberrantly spliced CEP290 is much
higher in photoreceptor-like cells compared to other cells that were investigated [16]. Therefore,
although the generation of these optic cups is a time-consuming and not yet a trivial process, this
cellular system would probably be most useful to assess the true ability of AONs to rescue CEP290
protein function in cells from patients with compound heterozygous mutations and illustrates the
limitations of the fibroblast system that we have employed here.
Following the use of AONs to rescue the splice defects in CEP290 associated with the
c.2991+1655A>G in humanized transgenic mice, and in cell lines from LCA patients homozygous
for this deep-intronic mutation [14–17], a clinical trial investigating the safety and efficacy of these
molecules for the treatment of CEP290-associated LCA has now commenced (NCT03140969 [23]).
In this study, individuals that are compound heterozygous for the c.2991+1655A>G mutation are
also recruited. As these AONs are delivered via intraocular injections, and the main target cells are
non-dividing neurons, the duration of a potentially positive effect will mainly depend on the stability
of the AON itself. This has been supported by other studies performed in animals using AONs that
were delivered to the retina and showed that their effect could be detected after 4–12 weeks [17,27–29].
In addition, the first AON drug approved for human administration was Fomivirsen (Vitravene), which
was delivered to the retina to treat CMV-retinitis [30,31]. How well LCA patients with compound
heterozygous mutations will respond to an AON administration for CEP290-associated LCA remains
to be established.
In summary, we previously identified an AON molecule that corrected CEP290 pre-mRNA
splicing, increased the CEP290 protein levels and restored a cellular defect in fibroblast cells
homozygously carrying the c.2991+1655A>G mutation. Here, we assessed whether the correction of a
single allele can also have a potential therapeutic effect. Overall, our results suggest that correcting one
allele might be enough to minimize the effects of the pathology, although the severity of the second
variant or the presence of other variants in ciliary genes needs to be taken into account.
4. Materials and Methods
4.1. Study Design
This study was performed using a total of 10 fibroblast cell lines. Groups were divided as
follows: three control lines derived from healthy individuals; three c.2991+1655A>G homozygous
lines derived from LCA patients; three compound heterozygous lines from LCA patients carrying
the c.2991+1655A>G in one allele and a stop mutation in trans (two of them: p.Gly1890* and another
p.Lys1575*) and one carrier individual (mother of an affected individual) presenting the deep-intronic
variant on one allele. For all experiments all cell lines were processed at the same time and all
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experiments were performed in duplicate (n = 2). The AON efficacy was assessed at RNA level by
RT-PCR, at protein level by Western blot and at cellular level by immunocytochemistry (ICC).
4.2. Patient-Derived Fibroblast Cells
Our research was conducted according to the tenets of the Declaration of Helsinki. The procedures
for obtaining human skin biopsies to establish primary fibroblasts cell lines were approved by
the Ethical Committee of the Radboud University Medical Center (Commissie Mensgebonden
Onderzoek Arnhem-Nijmegen, file number 2015-1543, permission granted on 28 September 2015).
Written informed consent was obtained from all participating individuals.
4.3. Cell Culture and AON Transfections
Fibroblast cell lines derived from individuals with CEP290-associated LCA and healthy or carrier
controls were cultured in Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 20% fetal
calf serum (FCS), 1% penicillin-streptomycin and 1% sodium pyruvate at 37 ◦C and 5% CO2. For each
analysis, cells were seeded in the corresponding plates. The next day, cells were transfected with AON
(0.1 µM final concentration) using FuGENE® HD Transfection Reagent (Promega, Madison, WI, USA)
according to the manufacturer’s protocol.
4.4. RNA Analysis
Cells were seeded and grown in 12-well plates and transfected with or without AON.
Forty-eight-hour post-transfection, cells were harvested and subjected to RNA isolation
using Nucleospin RNA isolation kit (Machery Nagel, Düren, Germany) following the
manufacturer’s protocol. One microgram of RNA was used for cDNA synthesis using iScript cDNA
synthesis kit (Bio-Rad, Hercules, CA, USA). Subsequently, cDNA was diluted by adding 50 µL of H2O.
PCR was performed with 10 µM of each primer pair, 2 µM of dNTPs, 1.5 mM MgCl2, 10% Q-solution
(Qiagen, Venlo, The Netherlands), 1 U of Taq polymerase (Roche, Penzberg, Germany) and 5 µL of
diluted cDNA in a total reaction of 25 µL using the following PCR conditions: 94 ◦C for 2 min, followed
by 35 cycles of 20 s at 94 ◦C, 20 s at 58 ◦C and 35 s at 72 ◦C, with a final extension step of 2 min at
72 ◦C. Amplicons were resolved in a 2% agarose gel. Actin (ACTB) was used as loading control.
For CEP290 the following primers were used: forward 5′-TGCTAAGTACAGGGACATCTTGC-3′ and
reverse 5′-AGACTCCACTTGTTCTTTTAAGGAG-3′; for ACTB: forward 5′-ACTGGGACGACATGG
AGAAG-3′ and reverse 5′-TCTCAGCTGTGGTGGTGAAG-3′.
4.5. Western Blot Analysis
Cells were grown in 10-cm dishes and transfected with or without 0.1 µM of AON. Forty-eight
hours post-transfection, cells were serum-starved for another 48 h. Subsequently, cells were harvested
and homogenized in 130 µL of RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP40, 0.1%
SDS, 0.5% Sodium deoxycholate, 1 mM EDTA supplemented with protease inhibitors). Total protein
was quantified using the BCA kit (Thermo Fisher Scientific, Waltham, MA, USA) as previously
described [6,17]. Briefly, for CEP290 immunodetection, ~75 µg of protein lysate was loaded onto a
NuPage 3–8% tris-acetate gel (Life Technologies, Carlsbad, CA, USA) and run for approximately 4 h at
100 V. Around 25 µg of the same protein lysates were loaded onto a NuPage 4–12% bis-acrylamide
tris-glycine gel (Life Technologies, Carlsbad, CA, USA) for the detection of α-Tubulin. Proteins were
transferred to a PVDF membrane (GE Healthcare, Little Chalfont, UK) overnight at 20 V at 4 ◦C.
Blots were blocked in 5% non-fat milk in PBS for 6 h at 4 ◦C and incubated for 3 days with antibodies
against CEP290 (rabbit, 1:750, Novus Biological, Littleton, CO, USA) or α-Tubulin (mouse, 1:2000,
Abcam, Cambridge, UK) in 0.5% non-fat milk in PBS at 4 ◦C. After primary antibody incubation,
blots were washed 3 times in PBS with 0.1% Tween-20 for 5 min, incubated with secondary antibody
(Goat anti-Rabbit, IRDye 800, 1:20,000 or Goat anti-Mouse, IRDye800, 1:20,000 from Li-Cor Biosciences,
Lincoln, NE, USA) for 1 h at room temperature (RT), and washed in PBS with 0.1% Tween-20 for 5 min.
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Blots were developed using the Odyssey Imaging System (Li-Cor Biosciences, Lincoln, NE, USA).
Detected bands were quantified using Fiji Software (1.47v, National Institute of Health, Bethesda, MD,
USA) [32]. Band quantification was conducted twice in each replicate and values were normalized to
those obtained for Tubulin. Statistical analysis was performed using Mann-Whitney test.
4.6. Immunocytochemistry Analysis
Cells were grown on coverslips in 12-well plates and transfected with or without 0.1 µM of AON.
Forty-eight hours post-transfection, cells were serum starved for another 48 h. Subsequently, cells were
rinsed in 1× PBS, fixed in 2% paraformaldehyde for 20 min at RT, permeabilized in PBS supplemented
with 1% Triton X for 5 min at RT and blocked for 30 min in 2% bovine serum albumin in 1× PBS at RT.
For the immunostaining, cells were incubated 60 min in blocking solution containing a 1:1000 dilution
of an anti-Acetylated α-Tubulin mouse monoclonal antibody (T6793, Sigma Aldrich, St. Louis, MO,
USA) at RT. Cells were washed for 3 × 5 min in 1× PBS, incubated for 45 min with the corresponding
secondary antibody (1:500 Goat anti-Mouse Alexa fluor 568 (Life Technologies, Carlsbad, CA, USA)
diluted in blocking solution. Cells were washed 3 × 5 min in 1× PBS and rinsed in water. Finally,
coverslips were mounted in Vectashield with DAPI and imaged on a Zeiss Axio Imager Z1 Fluorescense
microscope (Zeiss, Oberkochen, Germany). For each condition, a minimum of 110 ciliated cells were
analysed for cilium measurements using Fiji software [32]. Samples were compared using a two-tailed
Student’s t-test.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/3/
753/s1.
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AON Antisense oligonucleotide
CEP290 Centrosomal protein of 290 kDa
IRD Inherited retinal dystrophy
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References
1. Den Hollander, A.I.; Roepman, R.; Koenekoop, R.K.; Cremers, F.P. Leber congenital amaurosis: Genes,
proteins and disease mechanisms. Prog. Retin. Eye Res. 2008, 27, 391–419. [CrossRef] [PubMed]
2. RetNet. Available online: https://sph.uth.edu/RETNET (accessed on 24 January 2018).
3. Koenekoop, R.K. An overview of Leber congenital amaurosis: A model to understand human retinal
development. Surv. Ophthalmol. 2004, 49, 379–398. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 753 11 of 12
4. Stone, E.M. Leber congenital amaurosis—A model for efficient genetic testing of heterogeneous disorders:
LXIV Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 2007, 144, 791–811. [CrossRef] [PubMed]
5. Craige, B.; Tsao, C.C.; Diener, D.R.; Hou, Y.; Lechtreck, K.F.; Rosenbaum, J.L.; Witman, G.B. CEP290 tethers
flagellar transition zone microtubules to the membrane and regulates flagellar protein content. J. Cell Biol.
2010, 190, 927–940. [CrossRef] [PubMed]
6. Garanto, A.; van Beersum, S.E.; Peters, T.A.; Roepman, R.; Cremers, F.P.; Collin, R.W. Unexpected CEP290
mRNA splicing in a humanized knock-in mouse model for Leber congenital amaurosis. PLoS ONE 2013, 8, e79369.
[CrossRef] [PubMed]
7. Garcia-Gonzalo, F.R.; Corbit, K.C.; Sirerol-Piquer, M.S.; Ramaswami, G.; Otto, E.A.; Noriega, T.R.; Seol, A.D.;
Robinson, J.F.; Bennett, C.L.; Josifova, D.J.; et al. A transition zone complex regulates mammalian ciliogenesis
and ciliary membrane composition. Nat. Genet. 2011, 43, 776–784. [CrossRef] [PubMed]
8. Valente, E.M.; Silhavy, J.L.; Brancati, F.; Barrano, G.; Krishnaswami, S.R.; Castori, M.; Lancaster, M.A.;
Boltshauser, E.; Boccone, L.; Al-Gazali, L.; et al. Mutations in CEP290, which encodes a centrosomal protein,
cause pleiotropic forms of Joubert syndrome. Nat. Genet. 2006, 38, 623–625. [CrossRef] [PubMed]
9. Coppieters, F.; Lefever, S.; Leroy, B.P.; De Baere, E. CEP290, a gene with many faces: Mutation overview and
presentation of CEP290base. Hum. Mutat. 2010, 31, 1097–1108. [CrossRef] [PubMed]
10. Drivas, T.G.; Wojno, A.P.; Tucker, B.A.; Stone, E.M.; Bennett, J. Basal exon skipping and genetic pleiotropy:
A predictive model of disease pathogenesis. Sci. Transl. Med. 2015, 7. [CrossRef] [PubMed]
11. Perrault, I.; Delphin, N.; Hanein, S.; Gerber, S.; Dufier, J.L.; Roche, O.; Defoort-Dhellemmes, S.; Dollfus, H.;
Fazzi, E.; Munnich, A.; et al. Spectrum of NPHP6/CEP290 mutations in Leber congenital amaurosis and
delineation of the associated phenotype. Hum. Mutat. 2007, 28, 416. [CrossRef] [PubMed]
12. Vallespin, E.; Lopez-Martinez, M.A.; Cantalapiedra, D.; Riveiro-Alvarez, R.; Aguirre-Lamban, J.;
Avila-Fernandez, A.; Villaverde, C.; Trujillo-Tiebas, M.J.; Ayuso, C. Frequency of CEP290 c.2991_1655A>G
mutation in 175 Spanish families affected with Leber congenital amaurosis and early-onset retinitis
pigmentosa. Mol. Vis. 2007, 13, 2160–2162. [PubMed]
13. Den Hollander, A.I.; Koenekoop, R.K.; Yzer, S.; Lopez, I.; Arends, M.L.; Voesenek, K.E.; Zonneveld, M.N.;
Strom, T.M.; Meitinger, T.; Brunner, H.G.; et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause
of Leber congenital amaurosis. Am. J. Hum. Genet. 2006, 79, 556–561. [CrossRef] [PubMed]
14. Collin, R.W.; den Hollander, A.I.; van der Velde-Visser, S.D.; Bennicelli, J.; Bennett, J.; Cremers, F.P. Antisense
Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in
CEP290. Mol. Ther. Nucleic Acids 2012, 1, e14. [CrossRef] [PubMed]
15. Gerard, X.; Perrault, I.; Hanein, S.; Silva, E.; Bigot, K.; Defoort-Delhemmes, S.; Rio, M.; Munnich, A.;
Scherman, D.; Kaplan, J.; et al. AON-mediated Exon Skipping Restores Ciliation in Fibroblasts Harboring the
Common Leber Congenital Amaurosis CEP290 Mutation. Mol. Ther. Nucleic Acids 2012, 1, e29. [CrossRef]
[PubMed]
16. Parfitt, D.A.; Lane, A.; Ramsden, C.M.; Carr, A.J.; Munro, P.M.; Jovanovic, K.; Schwarz, N.; Kanuga, N.;
Muthiah, M.N.; Hull, S.; et al. Identification and Correction of Mechanisms Underlying Inherited Blindness
in Human iPSC-Derived Optic Cups. Cell Stem Cell 2016, 18, 769–781. [CrossRef] [PubMed]
17. Garanto, A.; Chung, D.C.; Duijkers, L.; Corral-Serrano, J.C.; Messchaert, M.; Xiao, R.; Bennett, J.;
Vandenberghe, L.H.; Collin, R.W. In vitro and in vivo rescue of aberrant splicing in CEP290-associated
LCA by antisense oligonucleotide delivery. Hum. Mol. Genet. 2016, 25, 2552–2563. [PubMed]
18. Bonifert, T.; Gonzalez Menendez, I.; Battke, F.; Theurer, Y.; Synofzik, M.; Schols, L.; Wissinger, B. Antisense
Oligonucleotide Mediated Splice Correction of a Deep Intronic Mutation in OPA1. Mol. Ther. Nucleic Acids
2016, 5, e390. [CrossRef] [PubMed]
19. Slijkerman, R.W.; Vache, C.; Dona, M.; Garcia-Garcia, G.; Claustres, M.; Hetterschijt, L.; Peters, T.A.;
Hartel, B.P.; Pennings, R.J.; Millan, J.M.; et al. Antisense Oligonucleotide-based Splice Correction for
USH2A-associated Retinal Degeneration Caused by a Frequent Deep-intronic Mutation. Mol. Ther.
Nucleic Acids 2016, 5, e381. [CrossRef] [PubMed]
20. Murray, S.F.; Jazayeri, A.; Matthes, M.T.; Yasumura, D.; Yang, H.; Peralta, R.; Watt, A.; Freier, S.; Hung, G.;
Adamson, P.S.; et al. Allele-Specific Inhibition of Rhodopsin with an Antisense Oligonucleotide Slows
Photoreceptor Cell Degeneration. Investig. Ophthalmol. Vis. Sci. 2015, 56, 6362–6375. [CrossRef] [PubMed]
21. Hammond, S.M.; Wood, M.J. Genetic therapies for RNA mis-splicing diseases. Trends Genet. 2011, 27,
196–205. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 753 12 of 12
22. Shimada, H.; Lu, Q.; Insinna-Kettenhofen, C.; Nagashima, K.; English, M.A.; Semler, E.M.; Mahgerefteh, J.;
Cideciyan, A.V.; Li, T.; Brooks, B.P.; et al. In Vitro Modeling Using Ciliopathy-Patient-Derived Cells Reveals
Distinct Cilia Dysfunctions Caused by CEP290 Mutations. Cell Rep. 2017, 20, 384–396. [CrossRef] [PubMed]
23. ClinicalTrials.gov. Available online: https://www.clinicaltrials.gov/ (accessed on 24 January 2018).
24. Plotnikova, O.V.; Pugacheva, E.N.; Golemis, E.A. Primary cilia and the cell cycle. Methods Cell Biol. 2009, 94,
137–160. [PubMed]
25. Kumar, A.; Rajendran, V.; Sethumadhavan, R.; Purohit, R. CEP proteins: The knights of centrosome dynasty.
Protoplasma 2013, 250, 965–983. [CrossRef] [PubMed]
26. Song, H.; Park, J.E.; Jang, C.Y. DDA3 targets Cep290 into the centrosome to regulate spindle positioning.
Biochem. Biophys. Res. Commun. 2015, 463, 88–94. [CrossRef] [PubMed]
27. Gerard, X.; Perrault, I.; Munnich, A.; Kaplan, J.; Rozet, J.M. Intravitreal Injection of Splice-switching
Oligonucleotides to Manipulate Splicing in Retinal Cells. Mol. Ther. Nucleic Acids 2015, 4, e250. [CrossRef]
[PubMed]
28. Shen, W.Y.; Garrett, K.L.; da Cruz, L.; Constable, I.J.; Rakoczy, P.E. Dynamics of phosphorothioate
oligonucleotides in normal and laser photocoagulated retina. Br. J. Ophthalmol. 1999, 83, 852–861. [CrossRef]
[PubMed]
29. Shen, W.Y.; Garrett, K.L.; Wang, C.G.; Zhang, K.; Ma, Z.Z.; Constable, I.J.; Rakoczy, P.E. Preclinical evaluation
of a phosphorothioate oligonucleotide in the retina of rhesus monkey. Lab. Investig. J. Tech. Methods Pathol.
2002, 82, 167–182. [CrossRef]
30. Anonymous. Fomivirsen approved for CMV retinitis: First antisense drug. AIDS Treat. News 1998, 7.
31. Roehr, B. Fomivirsen approved for CMV retinitis. J. Int. Assoc. Phys. AIDS Care 1998, 4, 14–16.
32. Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.;
Saalfeld, S.; Schmid, B.; et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 2012,
9, 676–682. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
